Irinotecan Hydrochloride Injection, Solution
Product Images NDC 25021-230

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Irinotecan Hydrochloride (NDC 25021-230). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Iri04 0009 01

Chemical structure diagram of irinotecan hydrochloride, displaying the molecular framework and key functional groups of this active pharmaceutical ingredient used in human prescription drugs.*

FDA Label Image

Iri04 0009 02

A Kaplan-Meier plot showing probability over time in months for two treatment groups: Irinotecan/5-FU/LV and 5-FU/LV. The y-axis is labeled 'Probability' and the x-axis 'Months'. The plot includes a p-value indication (p<0.05) from a log-rank test, comparing the two curves.*

FDA Label Image

Iri04 0009 03

A Kaplan-Meier survival probability curve comparing two treatment groups labeled Irinotecan/5-FU/LV and 5-FU/LV over a timeline of 0 to 30 months. The vertical axis shows survival probability ranging from 0 to 1, and the horizontal axis shows time in months. The graph includes a significance marker indicating p<0.05.*

FDA Label Image

Iri04 0009 04

A Kaplan-Meier survival curve comparing probability over months between Irinotecan and Best Supportive Care (BSC). The graph shows survival probabilities decreasing over time, with annotations indicating median follow-up of 13 months, median survival times of 9.2 months for Irinotecan and 6.5 months for BSC, and a p-value of 0.0001 based on a log-rank test.*

FDA Label Image

Iri04 0009 05

A Kaplan-Meier survival curve comparing the probability of survival over months between two treatments: Irinotecan and 5-FU (5-fluorouracil). The graph shows survival probability on the vertical axis and months on the horizontal axis, indicating median follow-up of 15 months, with Irinotecan showing a higher survival probability than 5-FU. A p-value of 0.035 is noted for the log-rank test.*

FDA Label Image

Iri04 0009 06

Label for Irinotecan Hydrochloride Injection, USP, 40 mg per 2 mL (20 mg/mL) single-dose vial by Sagent Pharmaceuticals. The vial is for intravenous use only and must be diluted before use. The label notes it is sterile, preservative-free, and includes storage instructions, cautioning that it is a cytotoxic agent. The product is made in China.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.